172 related articles for article (PubMed ID: 26479122)
21. Challenges in randomized controlled trials and emerging multiple sclerosis therapeutics.
Huang D
Neurosci Bull; 2015 Dec; 31(6):745-54. PubMed ID: 26480875
[TBL] [Abstract][Full Text] [Related]
22. Female sexual dysfunction in multiple sclerosis: Results of a survey among Dutch urologists and patients.
Scheepe JR; Alamyar M; Pastoor H; Hintzen RQ; Blok BF
Neurourol Urodyn; 2017 Jan; 36(1):116-120. PubMed ID: 26493281
[TBL] [Abstract][Full Text] [Related]
23. Update in vitamin D and multiple sclerosis.
Alharbi FM
Neurosciences (Riyadh); 2015 Oct; 20(4):329-35. PubMed ID: 26492110
[TBL] [Abstract][Full Text] [Related]
24. Potential role of immunoglobulin replacement therapy on MRI measures in multiple sclerosis: a systematic review.
Zare-Shahabadi A; Rashidian A; Sahraian MA; Rezaei N
Expert Rev Clin Immunol; 2015; 11(12):1291-5. PubMed ID: 26488634
[TBL] [Abstract][Full Text] [Related]
25. Stratification and monitoring of natalizumab-associated progressive multifocal leukoencephalopathy risk: recommendations from an expert group.
McGuigan C; Craner M; Guadagno J; Kapoor R; Mazibrada G; Molyneux P; Nicholas R; Palace J; Pearson OR; Rog D; Young CA
J Neurol Neurosurg Psychiatry; 2016 Feb; 87(2):117-25. PubMed ID: 26492930
[TBL] [Abstract][Full Text] [Related]
26. Proinflammatory GM-CSF-producing B cells in multiple sclerosis and B cell depletion therapy.
Li R; Rezk A; Miyazaki Y; Hilgenberg E; Touil H; Shen P; Moore CS; Michel L; Althekair F; Rajasekharan S; Gommerman JL; Prat A; Fillatreau S; Bar-Or A;
Sci Transl Med; 2015 Oct; 7(310):310ra166. PubMed ID: 26491076
[TBL] [Abstract][Full Text] [Related]
27. Orientation Dependent MR Signal Decay Differentiates between People with MS, Their Asymptomatic Siblings and Unrelated Healthy Controls.
Hernández-Torres E; Wiggermann V; Hametner S; Baumeister TR; Sadovnick AD; Zhao Y; Machan L; Li DK; Traboulsee A; Rauscher A
PLoS One; 2015; 10(10):e0140956. PubMed ID: 26489078
[TBL] [Abstract][Full Text] [Related]
28. Exploring strategies used following a group-based fatigue management programme for people with multiple sclerosis (FACETS) via the Fatigue Management Strategies Questionnaire (FMSQ).
Thomas S; Kersten P; Thomas PW; Slingsby V; Nock A; Jones R; Davies Smith A; Galvin KT; Baker R; Hillier C
BMJ Open; 2015 Oct; 5(10):e008274. PubMed ID: 26486976
[TBL] [Abstract][Full Text] [Related]
29. Patterns in workplace accommodations for people with multiple sclerosis to overcome cognitive and other disease-related limitations.
Leslie M; Kinyanjui B; Bishop M; Rumrill PD; Roessler RT
NeuroRehabilitation; 2015; 37(3):425-36. PubMed ID: 26484524
[TBL] [Abstract][Full Text] [Related]
30. Molecular Approach to Targeted Therapy for Multiple Sclerosis.
Sherbet GV
CNS Neurol Disord Drug Targets; 2016; 15(1):20-34. PubMed ID: 26560895
[TBL] [Abstract][Full Text] [Related]
31. Circulating microRNAs as Biomarkers of Alzheimer's Disease: A Systematic Review.
Wu HZ; Ong KL; Seeher K; Armstrong NJ; Thalamuthu A; Brodaty H; Sachdev P; Mather K
J Alzheimers Dis; 2016; 49(3):755-66. PubMed ID: 26484928
[TBL] [Abstract][Full Text] [Related]
32. Stage-Specific Role of Interferon-Gamma in Experimental Autoimmune Encephalomyelitis and Multiple Sclerosis.
Arellano G; Ottum PA; Reyes LI; Burgos PI; Naves R
Front Immunol; 2015; 6():492. PubMed ID: 26483787
[TBL] [Abstract][Full Text] [Related]
33. Relationship between brain volume loss and cognitive outcomes among patients with multiple sclerosis: a systematic literature review.
Vollmer T; Huynh L; Kelley C; Galebach P; Signorovitch J; DiBernardo A; Sasane R
Neurol Sci; 2016 Feb; 37(2):165-79. PubMed ID: 26537494
[TBL] [Abstract][Full Text] [Related]
34. Relapses Requiring Intravenous Steroid Use and Multiple-Sclerosis-related Hospitalizations: Integrated Analysis of the Delayed-release Dimethyl Fumarate Phase III Studies.
Giovannoni G; Gold R; Fox RJ; Kappos L; Kita M; Yang M; Sarda SP; Zhang R; Viglietta V; Havrdova E
Clin Ther; 2015 Nov; 37(11):2543-51. PubMed ID: 26526385
[TBL] [Abstract][Full Text] [Related]
35. Successful Replication of GWAS Hits for Multiple Sclerosis in 10,000 Germans Using the Exome Array.
Dankowski T; Buck D; Andlauer TF; Antony G; Bayas A; Bechmann L; Berthele A; Bettecken T; Chan A; Franke A; Gold R; Graetz C; Haas J; Hecker M; Herms S; Infante-Duarte C; Jöckel KH; Kieseier BC; Knier B; Knop M; Kümpfel T; Lichtner P; Lieb W; Lill CM; Limmroth V; Linker RA; Loleit V; Meuth SG; Moebus S; Müller-Myhsok B; Nischwitz S; Nöthen MM; Paul F; Pütz M; Ruck T; Salmen A; Stangel M; Stellmann JP; Strauch K; Stürner KH; Tackenberg B; Then Bergh F; Tumani H; Waldenberger M; Weber F; Wiendl H; Wildemann B; Zettl UK; Ziemann U; Zipp F; Hemmer B; Ziegler A;
Genet Epidemiol; 2015 Dec; 39(8):601-8. PubMed ID: 26497834
[TBL] [Abstract][Full Text] [Related]
36. Genes and Environment in Multiple Sclerosis project: A platform to investigate multiple sclerosis risk.
Xia Z; White CC; Owen EK; Von Korff A; Clarkson SR; McCabe CA; Cimpean M; Winn PA; Hoesing A; Steele SU; Cortese IC; Chitnis T; Weiner HL; Reich DS; Chibnik LB; De Jager PL
Ann Neurol; 2016 Feb; 79(2):178-89. PubMed ID: 26583565
[TBL] [Abstract][Full Text] [Related]
37. miR-27a and miR-214 exert opposite regulatory roles in Th17 differentiation via mediating different signaling pathways in peripheral blood CD4+ T lymphocytes of patients with relapsing-remitting multiple sclerosis.
Ahmadian-Elmi M; Bidmeshki Pour A; Naghavian R; Ghaedi K; Tanhaei S; Izadi T; Nasr-Esfahani MH
Immunogenetics; 2016 Jan; 68(1):43-54. PubMed ID: 26563334
[TBL] [Abstract][Full Text] [Related]
38. The effect of disease-modifying therapies on brain atrophy in patients with clinically isolated syndrome: a systematic review and meta-analysis.
Tsivgoulis G; Katsanos AH; Grigoriadis N; Hadjigeorgiou GM; Heliopoulos I; Papathanasopoulos P; Dardiotis E; Kilidireas C; Voumvourakis K;
Ther Adv Neurol Disord; 2015 Sep; 8(5):193-202. PubMed ID: 26557896
[TBL] [Abstract][Full Text] [Related]
39. Protein-Based Classifier to Predict Conversion from Clinically Isolated Syndrome to Multiple Sclerosis.
Borràs E; Cantó E; Choi M; Maria Villar L; Álvarez-Cermeño JC; Chiva C; Montalban X; Vitek O; Comabella M; Sabidó E
Mol Cell Proteomics; 2016 Jan; 15(1):318-28. PubMed ID: 26552840
[TBL] [Abstract][Full Text] [Related]
40. Alemtuzumab for multiple sclerosis: Long term follow-up in a multi-centre cohort.
Willis MD; Harding KE; Pickersgill TP; Wardle M; Pearson OR; Scolding NJ; Smee J; Robertson NP
Mult Scler; 2016 Aug; 22(9):1215-23. PubMed ID: 26514979
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
